Na Mee 1, 2025, Hansoh Pharmaceutical kwupụtara na ọgwụ mgbochi-ọgwụ B7-H4 nke otu ahụ mepụtara n'onwe ya (ADC) HS-20089 maka ịgba ọgwụ enwetala ikike itinye ya dị ka ọgwụ a họpụtara maka ọgwụgwọ Breakthrough-Therapy site na National Medical Products Administration (NMPA) nke China, yana ihe atụ a tụrụ aro maka kansa epithelial ovarian, kansa fallopian tube ma ọ bụ ọrịa kansa peritoneal mbụ na-eguzogide platinum.
Nsonaazụ sitere na ọmụmụ Phase I HS-20089-101 na ọmụmụ Phase II HS-20089-201 kwadoro aha a. Ọmụmụ HS-20089-101 bụ nnwale ahụike Phase I nke nwere ọtụtụ etiti, nke mepere emepe iji nyochaa nchekwa, ndidi, ọgwụ, na irè nke HS-20089 maka ịgba ọgwụ n'ime ndị ọrịa nwere etuto siri ike dị elu. Ọmụmụ HS-20089-201 bụ nnwale ahụike Phase II nke nwere ọtụtụ etiti, nke mepere emepe iji nyochaa irè, nchekwa, profaịlụ pharmacokinetic, na immunogenicity nke HS-20089 n'ime ndị ọrịa nwere kansa ovarian ugboro ugboro ma ọ bụ metastatic na kansa endometrial.
HS-20089 bụ ADC nke B7-H4 lekwasịrị anya, nke nwere topoisomerase inhibitor (TOPOi) a na-emepụta maka ọgwụgwọ nke kansa ovarian na ọrịa kansa ndị ọzọ na-efe efe n'ọtụtụ nnwale ahụike na China, ebe nyocha kachasị elu bụ nnwale ahụike nke Phase III. B7-H4 bụ glycoprotein nke na-ahụ maka mgbochi ọrịa transmembrane nke a na-egosipụta nke ọma na ọtụtụ ọrịa kansa siri ike, gụnyere kansa endometrial na kansa ovarian, mana ọ nwere obere ngosipụta na anụ ahụ nkịtị.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Ozi ịntanetị:myimmnet@163.com
Oge ozi: Mee-09-2025